Company intelligence / Profile preview

Jacob Thyssen

Ballerup, Denmark

Ownership: Private
Employees: ~4000
Development stage: Other

Overview

LEO Pharma has an advanced dermatology pipeline, including the biologic tralokinumab (anti-IL-13), which has shown statistically significant efficacy and safety for atopic dermatitis of the hands and other difficult-to-treat anatomical regions. Other late-stage assets include delgocitinib (a topical JAK inhibitor) and an anti-IL-22 receptor program. The company utilizes a search-and-develop model and partnerships to source innovative therapies for dermatological diseases lacking effective treatments.

Therapeutic areas: Dermatology
Modalities: Monoclonal antibodySmall moleculeTopical therapyBiologic
Industry: Biotech

Partnerships

TKL Research (US biotechs on topical therapies)

Beyond the preview

Go deeper on Jacob Thyssen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jacob Thyssen.

Explore the full profile